Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Upgraded by Wall Street Zen

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Friday.

Several other equities research analysts also recently commented on the stock. Royal Bank Of Canada restated a "sector perform" rating and issued a $5.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 14th. Oppenheimer reduced their target price on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. Finally, HC Wainwright restated a "neutral" rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $9.75.

Inovio Pharmaceuticals Stock Down 3.3%

Inovio Pharmaceuticals stock traded down $0.07 on Friday, hitting $2.04. The company's stock had a trading volume of 907,444 shares, compared to its average volume of 639,868. The firm has a market cap of $74.81 million, a P/E ratio of -0.64 and a beta of 1.34. The company has a fifty day moving average price of $1.99 and a 200-day moving average price of $1.95. Inovio Pharmaceuticals has a one year low of $1.42 and a one year high of $12.33.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.23. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.01 million. Analysts anticipate that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in INO. Nomura Holdings Inc. acquired a new position in Inovio Pharmaceuticals during the 1st quarter worth about $28,000. Alpine Global Management LLC acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth about $31,000. Freedom Investment Management Inc. acquired a new position in Inovio Pharmaceuticals during the 1st quarter worth about $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 5,894 shares in the last quarter. Finally, Bank of Montreal Can acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth about $43,000. Institutional investors and hedge funds own 26.79% of the company's stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.